University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Byron C. Hann, MD, PhD

Byron C. Hann, MD, PhD

Associate Researcher, Manager of Preclinical Therapeutics Core, UCSF Helen Diller Family Comprehensive Cancer Center

Education

Reed College, Portland, Oregon, B.A., 1984, Physics
University of California, San Francisco, CA, Medical Scientist’s Training Program
University of California, San Francisco, CA, Ph.D., 1992, Biochemistry and Biophysics
University of California, San Francisco, CA, M.D., 1994, School of Medicine


Professional Experience

  • 1983-1984
    Undergraduate: Senior Thesis, Physics, Chemistry Department, Reed College, "UV Spectroscopy of Wursters Blue; A Test of Huckel MO Theory". Advisors; Drs. Rich Bettega, Dennis Hoffman
  • 1984
    Research Assistant, Laboratory of Dr. Steve Arch, Reed College Dept. of Biology. Analysis of neuropeptides released by bag cells of Aplysia californica.
  • 1984-1985
    Post Graduate Research Physiologist, Laboratory of Dr. Louis Reichardt, UCSF School of Medicine, Dept of Physiology, Division of Neuroscience. Purification, characterization and cloning of a laminin binding protein.
  • 1988-1992
    Ph.D. candidate, Laboratory of Dr. Peter Walter, UCSF School of Medicine, Dept. of Biochemistry and Biophysics. Identification and analysis of the signal recognition particle in Saccharomyces cerevisiae.
  • 1994-1997
    Post-doctoral fellow, Laboratory of Prof. David Lane, CRC Labs, Department of Biochemistry, University of Dundee, Scotland. Phospho-regulation of p53: Identification of novel sites of p53 phosphorylation, generation of phospho-peptide antibodies, characterization of ATM, ATR phosphorylation of p53 in collaboration with S. Jackson Lab (Cambridge, England).
  • 1997-1999
    Associate Scientist, Onyx Pharmaceuticals, Richmond, CA, Viral therapy and Cell Cycle groups. Analysis of the mechanism of action and selectivity of an onco-lytic, E1B 55-K deficient adenovirus (ONYX-015).
  • 1999-2004
    Specialist, Laboratory of Dr. Allan Balmain, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco CA. The role of p53 in regulating viral and cellular processes in primary and tumor human cells infected with E1B 55-K deficient adenoviruses. p53 dependent abrogation of 55-K deficient virus replication.
  • 2004-present
    Associate Researcher, Director of UCSF Preclinical Core. Working closely with UCSF Breast and Prostate SPORE programs, RTK U54 program, and Pancreas Cancer Research Group to develop new animal models for preclinical studies and to oversee preclinical trials testing novel experimental therapeutics, diagnostics and imaging strategies.

Honors & Awards

  • 1984
  • Phi Beta Kappa
  • President's Award for Excellence in Scholarship, Reed College, Portland, OR

Selected Publications

  1. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107.
    View on PubMed
  2. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 Sep; 15(9):1221-1229.
    View on PubMed
  3. Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 Aug 15; 77(16):4498-4505.
    View on PubMed
  4. Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR. A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. J Med Chem. 2016 Dec 22; 59(24):11161-11170.
    View on PubMed
  5. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Dec 01; 126(12):4640-4653.
    View on PubMed
  6. Rozanov D, Cheltsov A, Sergienko E, Vasile S, Golubkov V, Aleshin AE, Levin T, Traer E, Hann B, Freimuth J, Alexeev N, Alekseyev MA, Budko SP, Bächinger HP, Spellman P. TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. PLoS One. 2015; 10(6):e0129566.
    View on PubMed
  7. Li X, Colvin T, Rauch JN, Acosta-Alvear D, Kampmann M, Dunyak B, Hann B, Aftab BT, Murnane M, Cho M, Walter P, Weissman JS, Sherman MY, Gestwicki JE. Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Mol Cancer Ther. 2015 Mar; 14(3):642-8.
    View on PubMed
  8. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014 Aug 21; 8(4):1037-48.
    View on PubMed
  9. Davies JM, Robinson AE, Cowdrey C, Mummaneni PV, Ducker GS, Shokat KM, Bollen A, Hann B, Phillips JJ. Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. J Neurosurg. 2014 Feb; 120(2):331-6.
    View on PubMed
  10. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25.
    View on PubMed
  11. Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, Renslo AR, Sonenberg N, Walter P. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife. 2013 May 28; 2:e00498.
    View on PubMed
  12. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
    View on PubMed
  13. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013 Apr 01; 73(7):2070-81.
    View on PubMed
  14. LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):93-8.
    View on PubMed
  15. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A central role for RAF?MEK?ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012 Aug; 2(8):685-93.
    View on PubMed
  16. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, Barcellos-Hoff MH. TGFß1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011 Nov 01; 17(21):6754-65.
    View on PubMed
  17. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012 Jan 26; 31(4):419-31.
    View on PubMed
  18. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl). 2011 Sep; 89(9):877-89.
    View on PubMed
  19. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TßRI/II kinase inhibition with LY2109761. Cancer Res. 2011 Mar 15; 71(6):2339-49.
    View on PubMed
  20. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15; 70(4):1505-12.
    View on PubMed

Go to UCSF Profiles, powered by CTSI